STONY BROOK, N.Y. and ROME, ITALY – February 17, 2022 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, and its program development partner, EvviVax, S.R.L. ("Evvivax"), today announced the publication of a manuscript detailing [...]
STONY BROOK, N.Y. February 10, 2022 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the first quarter of fiscal 2022, ended December 31, 2021. “Applied DNA had an excellent [...]
STONY BROOK, N.Y. – February 3, 2022 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)- based DNA manufacturing and nucleic acid-based technologies, today announced that it will report fiscal 2022 first quarter financial results after market close on Thursday, February 10, [...]
STONY BROOK, N.Y. January 28, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), intends to deploy its Linea™ 1.0 COVID-19 Assay (the “Linea [...]
STONY BROOK, N.Y. – January 21, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has submitted a request to the U.S. Food and Drug Administration [...]
STONY BROOK, N.Y. – January 18, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs (ADCL), has seen COVID-19 testing levels increase greater than [...]
By John Shearman, January 11, 2022 In this op-ed, Shearman discusses the state of legalization on a federal level and how advocacy, research and education will be the ultimate catalyst when it comes to progress in our industry. Here we are entering a new year. Finally, many states in the United States have agreed [...]
Counterfeiting is unfortunately still a widespread problem in the supply chain, with the U.S. Customs and Border Protection (CBP) seizing more than $1.3 billion in goods in 2020. The CBP report, released in September 2021, indicated that handbags and wallets were the most frequently counterfeited type of product at 17 percent of all goods, followed closely by [...]
STONY BROOK, N.Y. – January 4, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs (ADCL), has received conditional approval from the New York State [...]